Thymosin Beta 4 (TB-500) is a 43-amino-acid actin-sequestering peptide studied in preclinical models for cardiac repair, wound healing, tissue regeneration, and anti-inflammatory activity.
Product definition
What is Thymosin Beta 4 (TB-500)?
Thymosin Beta 4 (TB-500) is a 43-amino-acid actin-sequestering peptide studied in preclinical models for cardiac repair, wound healing, tissue regeneration, and anti-inflammatory activity.
Thymosin Beta 4 is a naturally occurring 43-amino-acid peptide originally isolated from thymic tissue. As the most abundant actin-sequestering protein in most mammalian cells, it plays a central role in cytoskeletal dynamics by maintaining the pool of unpolymerized G-actin available for rapid mobilization during cell movement and repair.
In preclinical research, TB-500 has been studied in models of myocardial infarction (where it is associated with cardiomyocyte survival and reduced infarct size), wound healing (accelerated epidermal and dermal closure), hair follicle activation, and tendon/ligament injury. Its anti-inflammatory properties have been investigated in multiple models, with researchers noting effects on macrophage polarization and cytokine expression in injured tissue.
Research context
How is Thymosin Beta 4 (TB-500) described in the research literature?
TB-500 binds G-actin through its LKKTET motif, regulating actin polymerization and promoting cell migration — a key process in tissue repair. Preclinical research has associated this mechanism with accelerated wound closure, cardiac muscle recovery, and reduced fibrosis in animal injury models. Its systemic distribution of activity across multiple tissue types is a defining feature of its research profile.
Compound profile
Key facts about Thymosin Beta 4 (TB-500)
- Class
- Actin-sequestering peptide
- Amino acids
- 43
- Molecular weight
- ~4,961 Da
- Origin
- Thymic protein; now synthetic
- Key motif
- LKKTET (actin-binding domain)
- CAS
- 77591-33-4
- Research category
- Cardiac repair, wound healing, tissue regeneration
- Storage
- Lyophilized: −20°C. Reconstituted: 2–8°C, use within 30 days
Research areas
What research areas is Thymosin Beta 4 (TB-500) associated with?
- Studied in preclinical cardiac models for cardiomyocyte survival and infarct size reduction
- Investigated for wound closure acceleration and dermal regeneration in animal studies
- Examined for hair follicle activation and hair regrowth stimulation in rodent models
- Researched for tendon and ligament tissue repair in orthopedic preclinical protocols
- Explored for anti-inflammatory mechanisms including macrophage polarization in injury models
- Notable for systemic activity across cardiac, dermal, and musculoskeletal tissue in preclinical data
Research audience
Who researches Thymosin Beta 4 (TB-500)?
TB-500 is researched by scientists in cardiovascular biology, wound healing, orthopedic repair, dermatology preclinical work, and inflammation research. Its broad activity profile makes it a cross-disciplinary compound with relevance across multiple research categories.
Preclinical research overview
What does the preclinical literature say about Thymosin Beta 4 (TB-500)?
Thymosin Beta 4 was first characterized as the principal actin-sequestering protein in the thymus and has been studied as a potential repair peptide since the 1990s. The research group of Hanna Kleinman at the NIH was pivotal in establishing its wound-healing properties, and subsequent work has expanded the research base significantly across cardiac, neural, and musculoskeletal models.
In cardiac research, TB-500 administration in rodent myocardial infarction models has been associated with preserved ejection fraction, reduced scar formation, and promotion of angiogenesis in the infarct border zone. This line of investigation has produced multiple peer-reviewed publications and positioned TB-500 as a candidate for further study in cardiac regeneration research.
In wound-healing and dermal research, TB-500 has been studied for its effects on keratinocyte and endothelial cell migration — both critical for wound closure. The compound's ability to promote blood vessel formation (angiogenesis) in wound beds has been documented in multiple rodent cutaneous wound models.
Common questions
Frequently asked about Thymosin Beta 4 (TB-500)
Why is TB-500 often combined with BPC-157?
BPC-157 and TB-500 target different proposed mechanisms — BPC-157 through NO-system and angiogenesis in localized tissue models, TB-500 through actin regulation and systemic cell-migration promotion. Researchers studying tissue repair often combine them because the mechanisms appear complementary. The Wolverine Blend on this site combines both in a single research formulation.
What is the difference between TB-500 and Thymosin Beta 4?
TB-500 is the research peptide label for synthetic Thymosin Beta 4. The compounds are structurally identical — both are the same 43-amino-acid sequence. The TB-500 naming convention is used in research supply contexts to distinguish the synthetic analog from endogenous Thymosin Beta 4 in biological samples.
Is the cardiac research on TB-500 replicated across multiple labs?
Yes. The cardiac repair research profile on TB-500 includes work from multiple independent research groups beyond the original NIH studies, including groups focused on heart failure, ischemia-reperfusion injury, and stem cell activation. The breadth of independent replication is part of what makes TB-500 one of the more data-rich peptides in the cardiac repair research literature.
Research Use Only
Sold for laboratory and research purposes only. Not approved for, nor intended for, human or veterinary consumption, diagnostic use, or therapeutic application. These products have not been evaluated by the Food and Drug Administration. Keep out of reach of children. For use by qualified researchers only.
Nothing on this page constitutes medical advice, a treatment recommendation, or a clinical protocol. Consult a qualified healthcare provider before making any health or treatment decisions.
By accessing this product page you confirm that you are a qualified researcher aged 18 or older and that you will use this product solely for lawful laboratory research purposes. View Research Use Policy